Myeloproliferative Neoplasms

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with myelofibrosis to determine the value of mutational profiling in predicting outcomes after transplant.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.

The FDA has granted a priority review designation to a new drug application for fedratinib as a treatment for patients with myelofibrosis.

Suman A. Kambhampati, MD, discusses emerging data in myeloproliferative neoplasms and what is coming on the horizon.

Abdulraheem Yacoub, MD, discusses the development of interferon and its current role in the management of patients with myeloproliferative neoplasms.

Richard T. Silver, MD, discusses the history of interferon and shares insight on why the drug still holds its place in the treatment of patients with MPNs.

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.